Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
NCT ID: NCT04433234
Last Updated: 2025-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
8 participants
INTERVENTIONAL
2020-06-30
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
NCT02667483
Extension Study of NS-089/NCNP-02 in DMD
NCT05135663
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
NCT05996003
A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy
NCT03400852
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy
NCT06280209
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DS-5141b 2.0 mg/kg
Participants who will receive DS-5141b 2.0 mg/kg once weekly.
DS-5141b
Administered via subcutaneous injection once weekly
DS-5141b 6.0 mg/kg
Participants who will receive DS-5141b 6.0 mg/kg once weekly.
DS-5141b
Administered via subcutaneous injection once weekly
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DS-5141b
Administered via subcutaneous injection once weekly
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patient who does not consent to use appropriate contraception
* Patient not appropriate to participant in the study as determined by the Investigator
5 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daiichi Sankyo Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Study Leader
Role: STUDY_DIRECTOR
Daiichi Sankyo Co., Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Center of Neurology and Psychiatry
Tokyo, Kodaira-Shi, Japan
Kobe University Hospital
Hyōgo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
205321
Identifier Type: OTHER
Identifier Source: secondary_id
DS5141-A-J201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.